Confronto
Linaclotid vs. LL-37
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
851199-59-2
597562-32-8
Peso molecolare
1526.74 g/mol
4493.33 g/mol
Emivita
nessun dato
nessun dato
Sequenza
nessun dato
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESMeccanismo d'azione
Linaclotid
Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
0
4
di cui sull'uomo
0
1
Effetti registrati
2
4
Contraddizioni aperte
0
1
Eventi avversi documentati
1
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Linaclotid and LL-37?
- Linaclotid is classified as "Ricerca (altro)", while LL-37 is classified as "Ricerca (altro)". Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Linaclotid or LL-37?
- The highest available evidence level is "RCT sull'uomo" for Linaclotid and "Studio sull'uomo" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Linaclotid and LL-37 in Germany and the United States?
- Germania: Linaclotid — Su prescrizione, LL-37 — Solo ricerca. Stati Uniti: Linaclotid — Su prescrizione, LL-37 — Solo ricerca. These are factual summaries with source and review date on the individual pages.